f99fc327-6174-4e4e-a39b-18be90ab423f.jpeg
Right answer according to chemistry by pharmacology MBBS second year book for long question.
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Searching PubMed
artemisinin combination therapy resistance falciparum
Antimalarial Drugs — Long Question Answer (Pharmacology, MBBS II)
1. Classification of Antimalarial Drugs
The most clinically useful classification is based on the stage of the parasite's life cycle on which the drug acts, supplemented by a chemical classification.
A. Based on stage of action (clinical utility)
| Category | Action | Drugs |
|---|---|---|
| Tissue schizontocides (causal prophylactics) | Kill the primary liver (hepatic) schizont before it releases merozoites into blood → prevents the attack itself | Primaquine, Pyrimethamine, Proguanil |
| Tissue schizontocides for radical cure | Kill dormant hepatic hypnozoites of P. vivax/ovale → prevents relapse | Primaquine, Tafenoquine |
| Blood schizontocides | Act on erythrocytic (asexual) stage → terminate the clinical attack | Chloroquine, Quinine, Mefloquine, Artemisinin & derivatives (artesunate, artemether, arteether), Atovaquone-proguanil, Lumefantrine, Sulfadoxine-pyrimethamine, Doxycycline |
| Gametocytocides | Destroy sexual forms in blood → prevent transmission to mosquito | Primaquine (all species), artemisinins (partial) |
| Sporontocides | Prevent gametocyte maturation into sporozoites inside the mosquito | Primaquine, Pyrimethamine, Proguanil |
B. Based on chemical structure
- 4-Aminoquinolines – Chloroquine, Amodiaquine
- Quinoline-methanols – Quinine, Quinidine, Mefloquine
- 8-Aminoquinolines – Primaquine, Tafenoquine
- Biguanide – Proguanil
- Diaminopyrimidine – Pyrimethamine
- Sulfonamide/Sulfone – Sulfadoxine, Dapsone
- Antibiotics – Tetracycline, Doxycycline, Clindamycin, Azithromycin
- Sesquiterpene lactones (endoperoxides) – Artemisinin, Artesunate, Artemether, Arteether, Dihydroartemisinin
- Naphthoquinone – Atovaquone
- Aryl amino-alcohol – Lumefantrine, Halofantrine
2. Mechanism of Action and Adverse Effects of Major Drugs
Chloroquine
- MOA: A weak base that concentrates in the acidic parasite food vacuole; inhibits heme polymerase, preventing detoxification of free heme (ferriprotoporphyrin IX) into inert hemozoin. Accumulated free heme is toxic to the parasite membrane.
- Adverse effects: GI upset, pruritus (marked in dark-skinned individuals), headache, blurred vision, retinopathy (with prolonged high-dose use), bleaching of hair, skin rashes, ECG changes (QRS widening), hypotension/arrhythmia on rapid IV push, hemolysis in G6PD deficiency, exacerbation of psoriasis.
Quinine
- MOA: Same heme-polymerase inhibition; also intercalates parasite DNA. Used in chloroquine-resistant P. falciparum and severe malaria.
- Adverse effects: Cinchonism (tinnitus, headache, nausea, blurred vision, deafness), hypoglycemia (stimulates insulin release), hypotension, cardiotoxicity with rapid IV infusion, hemolysis in G6PD deficiency, blackwater fever, thrombocytopenia.
Artemisinin and derivatives (artesunate, artemether, arteether)
- MOA: The endoperoxide bridge is cleaved by heme iron in the parasite food vacuole, generating free radicals that alkylate parasite proteins (e.g., PfATP6) and membranes. Fastest-acting schizontocide; also active on young gametocytes.
- Adverse effects: Generally well tolerated - nausea, vomiting, dizziness, transient neutropenia, mild transaminase elevation; embryotoxicity seen in animal studies (caution in first trimester).
Primaquine
- MOA: Oxidant quinone-imine metabolites disrupt mitochondrial function of exoerythrocytic (hepatic) forms and gametocytes.
- Adverse effects: Hemolysis and methemoglobinemia in G6PD deficiency (mandatory G6PD testing before use), abdominal pain/nausea; contraindicated in pregnancy and infancy.
Mefloquine
- MOA: Forms a toxic complex with heme, similar to chloroquine.
- Adverse effects: Neuropsychiatric effects (nightmares, dizziness, psychosis, seizures - avoid in epilepsy/psychiatric illness), cardiac conduction disturbances, GI upset.
Pyrimethamine / Proguanil (± Sulfadoxine)
- MOA: Sequential blockade of folate synthesis - sulfonamide inhibits dihydropteroate synthase, pyrimethamine/cycloguanil (active metabolite of proguanil) inhibits dihydrofolate reductase → blocks DNA synthesis.
- Adverse effects: GI upset, megaloblastic anemia, folate deficiency; Sulfadoxine-pyrimethamine can cause Stevens-Johnson syndrome/toxic epidermal necrolysis.
Atovaquone-proguanil
- MOA: Atovaquone inhibits the parasite mitochondrial cytochrome bc1 electron transport complex, collapsing membrane potential.
- Adverse effects: GI upset, headache, mild transient hepatic enzyme rise.
Doxycycline
- MOA: Inhibits protein synthesis at the apicoplast ribosome.
- Adverse effects: Photosensitivity, GI upset, esophagitis; contraindicated in pregnancy and children under 8 years (teeth staining, bone growth inhibition).
(This mechanism and side-effect data is consistent across Lippincott's Illustrated Reviews Pharmacology and Katzung's Basic and Clinical Pharmacology.)
3. Regimens for Falciparum Malaria During Pregnancy
Pregnancy alters drug choice because of teratogenic/fetal risk with some antimalarials. Per WHO and India's National Vector Borne Disease Control Programme (NVBDCP) guidelines - Park's Textbook of PSM:
| Trimester | Preferred regimen |
|---|---|
| 1st trimester, uncomplicated P. falciparum | Quinine + Clindamycin for 7 days (artemisinin combinations avoided if an alternative exists, due to limited first-trimester safety data, though WHO now permits ACT if quinine is unavailable or has failed) |
| 2nd and 3rd trimester, uncomplicated P. falciparum | ACT - Artesunate + Sulfadoxine-Pyrimethamine (AS+SP) for 3 days, as used in the general population (or Artemether-Lumefantrine) |
| Severe/complicated malaria, any trimester | IV Artesunate is the drug of choice (superior survival to IV quinine per the SEAQUAMAT/AQUAMAT trial data), followed by a complete oral ACT course |
Drugs to avoid in pregnancy: Primaquine (fetal hemolysis risk, deferred until after delivery and lactation), Tetracyclines/Doxycycline (fetal bone and teeth effects), and mefloquine used only as a second-line option due to neuropsychiatric and possible stillbirth signal at high doses.
4. Artemisinin-Based Combination Therapies (ACTs) and Their Advantages
Rationale: Artemisinin derivatives have a very short half-life (achieving rapid, near-complete parasite clearance) but carry a high risk of recrudescence if used alone. Combining them with a slower-eliminating partner drug clears any residual parasites and provides mutual protection against resistance.
Common ACT regimens (3-day course):
- Artemether + Lumefantrine (Coartem) - fixed-dose, twice daily x 3 days
- Artesunate + Sulfadoxine-Pyrimethamine - India's national first-line regimen for P. falciparum
- Artesunate + Mefloquine
- Artesunate + Amodiaquine
- Dihydroartemisinin + Piperaquine
Advantages of ACTs over other antimalarials:
- Very rapid reduction in parasite biomass (parasite reduction ratio ~10⁴ per asexual cycle) → faster fever and symptom resolution than chloroquine or quinine.
- Gametocytocidal activity → reduces onward transmission to mosquitoes, a public-health advantage over drugs like SP alone.
- High efficacy against multidrug-resistant P. falciparum (chloroquine- and SP-resistant strains).
- The combination delays emergence of resistance - the short-acting artemisinin clears most parasites while the longer-acting partner mops up survivors, so neither drug is exposed as monotherapy.
- Short, well-tolerated 3-day courses improve compliance, with fewer serious adverse effects than quinine (no cinchonism, less cardiotoxicity).
- IV artesunate has proven mortality benefit over IV quinine in severe malaria.
- Recommended by WHO and NVBDCP as first-line treatment for both uncomplicated and severe P. falciparum malaria.
Important caveat for exam completeness: Partial artemisinin resistance (delayed parasite clearance linked to kelch13 mutations) is now documented in parts of Africa and Southeast Asia, and molecular surveillance has flagged resistance markers in India as well, which is prompting closer monitoring of ACT efficacy going forward (recent systematic reviews - PMID 41291512 on sub-Saharan Africa ACT efficacy trends 2010-2024, and PMID 38574550 on resistance markers in India). This doesn't change standard first-line ACT recommendations for now, but it's a point examiners may expect in a "recent advances" remark at the end of the answer.
Sources: Lippincott's Illustrated Reviews - Pharmacology; Katzung's Basic and Clinical Pharmacology, 16th Ed.; Goodman & Gilman's Pharmacological Basis of Therapeutics; Park's Textbook of Preventive and Social Medicine (malaria in pregnancy); Harrison's Principles of Internal Medicine 22E.
This is a shared conversation. Sign in to Orris to start your own chat.